Skip to main content
Springer Nature Link
Log in

Role of Biomarkers in Cancer Prevention and Therapy

  • Chapter
  • First Online:
Toxicology and Human Health

  • 566 Accesses

Abstract

Cancer is the second leading cause of morbidity and mortality globally because it is usually detected at advanced stages. If detected early, deaths by cancer can be reduced and survival can be prolonged. Different types of cells possess unique molecular signatures and characteristics in particular conditions, which can be measured objectively and serve as the biomarker for that condition. Various biomolecules present in tissues, blood, and other body fluids may indicate the presence of cancer. Cancer biomarkers are useful tools for risk assessment, early detection, diagnosis, prognosis, and recurrence of cancer. Identification of reliable biomarkers can bring a deep understanding of carcinogenesis and help guide the clinicians in early detection and treatment of cancer. In the field of oncology, biomarker discovery has revolutionized the process of cancer treatment by focusing on the actionable targets in a cancer patient.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alam A, Ansari MA, Badrealam KF (2021) Molecular approaches to lung cancer prevention. Future Oncol 17:1793–1810

    Article  CAS  PubMed  Google Scholar 

  • Allard WJ, Matera J, Miller MC et al (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10:6897–6904

    Article  PubMed  Google Scholar 

  • Antoniou A, Pharoah PD, Narod S (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Bast RC Jr, Feeney M, Lazarus H et al (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68:1331–1337

    Article  PubMed Central  PubMed  Google Scholar 

  • Bast RC Jr, Ravdin P, Hayes DF et al (2001) 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865–1878

    Article  PubMed  Google Scholar 

  • Bell H (1982) Alpha-fetoprotein and carcinoembryonic antigen in patients with primary liver carcinoma, metastatic liver disease, and alcoholic liver disease. Scand J Gastroenterol 17(7):897–903

    Article  CAS  PubMed  Google Scholar 

  • de Bono JS, Scher HI, Montgomery RB et al (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302–6309

    Article  PubMed  Google Scholar 

  • Chapman AM, Sun KY, Ruestow P et al (2016) Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers. Lung Cancer 102:122–134

    Article  PubMed  Google Scholar 

  • Chen KZ, Lou F, Yang F et al (2016) Circulating tumor DNA detection in early-stage non-small cell lung cancer patients by targeted sequencing. Sci Rep 24:31985

    Article  Google Scholar 

  • Cohen SJ, Punt CJ, Iannotti N et al (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26:3213–3221

    Article  PubMed  Google Scholar 

  • Coticchia CM, Yang J, Moses MA et al (2008) Ovarian cancer biomarkers: current options and future promise. J Natl Compr Canc Netw 6:795–802

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Cristofanilli M, Hayes DF, Budd GT et al (2005) Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23:1420–1430

    Article  PubMed  Google Scholar 

  • Duffy MJ (2005) Predictive markers in breast and other cancers: a review. Clin Chem 51:494–503

    Article  CAS  PubMed  Google Scholar 

  • Duffy MJ (2015) Use of biomarkers in screening for cancer. Adv Exp Med Biol 867:27–23

    Article  CAS  PubMed  Google Scholar 

  • Durand X, Moutereau S, Xylinas E et al (2011) Progensa™ PCA3 test for prostate cancer. Expert Rev Mol Diagn 11:137–144

    Article  CAS  PubMed  Google Scholar 

  • Ferrucci PF, Lens M, Cocorocchio E (2021) Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients. Curr Oncol Rep 23:138

    Article  CAS  PubMed  Google Scholar 

  • Gold P, Freedman SO (1965) Demonstration of tumor-specific antigens in human colonic carcinoma by immunological tolerance and absorption techniques. J Exp Med 121:439

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Gu X, Dong M, Liu Z (2019) Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer. Cancer Cell Int 19:146

    Article  PubMed Central  PubMed  Google Scholar 

  • Guedez L, Stetler-Stevenson WG (2010) The prognostic value of TIMP-1 in multiple myeloma. Leuk Res 34:576–577

    Article  CAS  PubMed  Google Scholar 

  • Halling KC, Kipp BR (2008) Bladder cancer detection using FISH (UroVysion assay). Adv Anat Pathol 15:279–286

    Article  CAS  PubMed  Google Scholar 

  • Hessvik NP, Llorente A (2018) Current knowledge on exosome biogenesis and release. Cell Mol Life Sci 75:193–208

    Article  CAS  PubMed  Google Scholar 

  • Hilkens J, Buijs F, Hilgers J et al (1984) Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 34:197–206

    Article  CAS  PubMed  Google Scholar 

  • Hough CD, Sherman-Baust CA, Pizer ES et al (2000) Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 60:6281–6287

    CAS  PubMed  Google Scholar 

  • Jia S, Zhang R, Li Z et al (2017) Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer. Oncotarget 8:55632–55645

    Article  PubMed Central  PubMed  Google Scholar 

  • Karim MA (2017) Cologuard test: A Possible Alternate to Colonoscopy? J Ayub Med Coll Abbottabad 29:1

    Google Scholar 

  • Kirchhoff C (1998) Molecular characterization of epididymal proteins. Rev Reprod 3:86–95

    Article  CAS  PubMed  Google Scholar 

  • Kondrashova O, Topp M, Nesic K et al (2018) Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun 9:3970

    Article  PubMed Central  PubMed  Google Scholar 

  • Konishi T, Shimada Y, Hsu M et al (2018) Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and colon cancer outcome. JAMA Oncol 4:309–315

    Article  PubMed  Google Scholar 

  • Koprowski H, Steplewski Z, Mitchell K et al (1979) Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 5:957–971

    Article  CAS  PubMed  Google Scholar 

  • Lech G, Słotwiński R, Słodkowski M (2016) Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. World J Gastroenterol 22:1745–1755

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Lee PI, Chang MH, Chen DS et al (1989) Serum alpha-fetoprotein levels in normal infants: a reappraisal of regression analysis and sex difference. J Pediatr Gastroenterol Nutr 8:19–25

    Article  CAS  PubMed  Google Scholar 

  • Li Destri G, Rubino AS, Latino R et al (2015) Preoperative carcinoembryonic antigen and prognosis of colorectal cancer. An independent prognostic factor still reliable. Int Surg 100:617–625

    Article  PubMed Central  PubMed  Google Scholar 

  • Lill C, Bachtiary B, Selzer E et al (2017) A 5-year update of patients with HPV positive versus negative oropharyngeal cancer after radiochemotherapy in Austria. Wien Klin Wochenschr 129(11):398–403

    Article  PubMed Central  PubMed  Google Scholar 

  • Louie AD, Huntington K, Carlsen L et al (2021) Integrating molecular biomarker inputs into development and use of clinical cancer therapeutics. Front Pharmacol 12:1–8

    Article  Google Scholar 

  • Malapelle U, Sirera R, Jantus-Lewintre E et al (2017) Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer. Expert Rev Mol Diagn 17:209–215

    Article  CAS  PubMed  Google Scholar 

  • Micke O, Bruns F, Schäfer U et al (2003) CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. Anticancer Res 23:835–840

    CAS  PubMed  Google Scholar 

  • Milani A, Montemurro F, Gioeni L et al (2010) Role of trastuzumab in the management of HER2-positive metastatic breast cancer. Breast Cancer 242:93–109

    Google Scholar 

  • Mondal A, Kumari DS, Panda S et al (2017) Extracellular vesicles as modulators of tumor microenvironment and disease progression in glioma. Front Oncol 7:144

    Article  PubMed Central  PubMed  Google Scholar 

  • Moretto R, Rossini D, Conca V (2021) CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. Br J Cancer 125:839–845

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • O’Brien TJ, Tanimoto H, Konishi I et al (1998) More than 15 years of CA 125: what is known about the antigen, its structure and its function. Int J Biol Markers 13:188–195

    Article  PubMed  Google Scholar 

  • Ozawa T, Matsuda K, Ishihara S et al (2021) The robust performance of carcinoembryonic antigen levels after adjuvant chemotherapy for the recurrence risk stratification in patients with colorectal cancer. J Surg Oncol 124:97–105

    Article  CAS  PubMed  Google Scholar 

  • Papsidero LD, Wang MC, Valenzuela LA et al (1980) Prostate antigen in sera of prostatic cancer patients. Cancer Res 40:2428–2432

    CAS  PubMed  Google Scholar 

  • Perrier A, Boelle PY, Chrétien Y et al (2020) An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies. PLoS One 15:e0227356

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672

    Article  CAS  PubMed  Google Scholar 

  • Primrose JN, Perera R, Gray A et al (2014) FACS Trial Investigators. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA 311:263–270

    Article  CAS  PubMed  Google Scholar 

  • Raposo G, Stoorvogel W (2013) Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 200:373–383

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Rathore R, Coward AR, Woywodt A (2012) What’s in a name? Bence Jones protein. Clin Kidney J 5:478–483

    Article  PubMed Central  PubMed  Google Scholar 

  • Saito S, Ojima H, Ichikawa H et al (2008) Molecular background of alpha-fetoprotein in liver cancer cells as revealed by global RNA expression analysis. Cancer Sci 99(12):2402–2409

    Article  CAS  PubMed  Google Scholar 

  • Sammallahti H, Kokkola A, Rezasoltani S et al (2021) Microbiota alterations and their association with oncogenomic changes in pancreatic cancer patients. Int J Mol Sci 22:12978

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Schummer M, Ng WV, Bumgarner RE et al (1999) Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 238:375–385

    Article  CAS  PubMed  Google Scholar 

  • Shimizu M, Yamauchi K (1982) Isolation and characterization of mucin-like glycoprotein in human milk fat globule membrane. J Biochem 91:515–524

    Article  CAS  PubMed  Google Scholar 

  • Siveen KS, Raza A, Ahmed E et al (2019) The role of extracellular vesicles as modulators of the tumor microenvironment, metastasis and drug resistance in colorectal cancer. Cancers 11:746

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Sobanski T, Arantes LMRB, Dos Santos W et al (2021) Methylation profile of colon cancer genes in colorectal precursor lesions and tumor tissue: perspectives for screening. Scand J Gastroenterol 56:920–928

    Article  CAS  PubMed  Google Scholar 

  • Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249

    Article  PubMed  Google Scholar 

  • Takada M, Toi M (2020) Neoadjuvant treatment for HER2-positive breast cancer. Chin Clin Oncol 9:32

    Article  PubMed  Google Scholar 

  • Van Cutsem E, Kohne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417

    Article  PubMed  Google Scholar 

  • Vietri MT, Molinari AM, Laura De Paola M et al (2012) Identification of a novel in-frame deletion in BRCA2 and analysis of variants of BRCA1/2 in Italian patients affected with hereditary breast and ovarian cancer. Clin Chem Lab Med 50:2171–2180

    Article  CAS  PubMed  Google Scholar 

  • Yang SX, Pollock HG, Rawitch AB (1996) Glycosylation in human thyroglobulin: location of the N-linked oligosaccharide units and comparison with bovine thyroglobulin. Arch Biochem Biophys 327:61–70

    Article  CAS  PubMed  Google Scholar 

  • Youssef O, Lahti L, Kokkola A et al (2018) Stool microbiota composition differs in patients with stomach, colon, and rectal neoplasms. Dig Dis Sci 63:2950–2958

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Preventive Oncology, Dr. B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

    Sujata Pathak & Asrar Alam

Authors
  1. Sujata Pathak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Asrar Alam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sujata Pathak .

Editor information

Editors and Affiliations

  1. Department of Biophysics, All India Institute of Medical Sciences, New Delhi, India

    Md. Irshad Ahmad

  2. Department of Biology, Qassim University, Buraydah, Saudi Arabia

    Mohammad Mahamood

  3. Department of Science, T.R. Kanya Mahavidyalaya, Aligarh, India

    Mehjbeen Javed

  4. College of Agriculture and Veterinary Medicine, Qassim University, Buraydah, Saudi Arabia

    Saleh S. Alhewairini

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pathak, S., Alam, A. (2023). Role of Biomarkers in Cancer Prevention and Therapy. In: Ahmad, M.I., Mahamood, M., Javed, M., Alhewairini, S.S. (eds) Toxicology and Human Health . Springer, Singapore. https://doi.org/10.1007/978-981-99-2193-5_8

Download citation

Publish with us

Policies and ethics